Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

doi:10.1016/j.drugalcdep.2015.06.022

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

Drug and alcohol dependence - 1 Sept 2015

Chen Li-Shiun, Baker Timothy B, Jorenby Douglas, Piper Megan, Saccone Nancy, Johnson Eric, Breslau Naomi, Hatsukami Dorothy, Carney Robert M, Bierut Laura J

Abstract excerpt

OBJECTIVE: Recent evidence suggests that the efficacy of smoking cessation pharmacotherapy can vary across patients based on their genotypes. This study tests whether the coding variant rs16969968 in the CHRNA5 nicotinic receptor gene predicts the effects of combination nicotine replacement therapy (cNRT) and varenicline on treatment outcomes. METHOD: In two randomized smoking cessation trials comparing cNRT vs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Variation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Nerve Tissue Proteins

Share to Receptors, Nicotinic

Share to Smoking

Share to Smoking Cessation

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 26142345
DOI: 10.1016/j.drugalcdep.2015.06.022
PMCID: PMC4537319

Genes

CHRNA5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.PMID 26142345Read ↗

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled TrialSemantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.Semantic proximity Read ↗

Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis.Semantic proximity Read ↗

Studies towards stratified approaches to smoking cessation with a focus on South Asians and effectiveness of vareniclineSemantic proximity Read ↗

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Semantic proximity Read ↗

A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation.Semantic proximity Read ↗

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Organic cation transporter variation and response to smoking cessation therapies.Semantic proximity Read ↗

The Role of Pharmacogenetics in Smoking.Semantic proximity Read ↗

Variants in nicotinic receptors and risk for nicotine dependence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.